Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

[The efficacy and tolerability of allopurinol dose escalation in patients with gout].

Radak-Perović M, Zlatković-Svenda M.

Srp Arh Celok Lek. 2013 May-Jun;141(5-6):333-6. Serbian.

2.

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.

Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR.

Ann Rheum Dis. 2009 Jun;68(6):892-7. doi: 10.1136/ard.2008.091462. Epub 2008 Jul 16.

PMID:
18633127
3.

A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.

Xu S, Liu X, Ming J, Chen S, Wang Y, Liu X, Liu H, Peng Y, Wang J, Lin J, Ji H, Liu B, Lu Y, Liu P, Zhang Y, Ji Q.

Int J Rheum Dis. 2015 Jul;18(6):669-78. doi: 10.1111/1756-185X.12648. Epub 2015 May 27.

PMID:
26013187
4.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

5.

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR.

Ann Rheum Dis. 2009 Jan;68(1):51-6. doi: 10.1136/ard.2007.083071. Epub 2008 Feb 4.

PMID:
18250112
6.

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Clin Pharmacol Ther. 2011 Sep;90(3):392-8. doi: 10.1038/clpt.2011.113. Epub 2011 Jul 27.

PMID:
21796116
7.

An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc.

PMID:
21654265
8.

Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.

Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R.

J Clin Pharm Ther. 2016 Jun;41(3):290-7. doi: 10.1111/jcpt.12391. Epub 2016 Apr 24.

PMID:
27109450
9.
10.

An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.

Huang X, Du H, Gu J, Zhao D, Jiang L, Li X, Zuo X, Liu Y, Li Z, Li X, Zhu P, Li J, Zhang Z, Huang A, Zhang Y, Bao C.

Int J Rheum Dis. 2014 Jul;17(6):679-86. doi: 10.1111/1756-185X.12266. Epub 2014 Jan 28.

PMID:
24467549
11.

Allopurinol: insights from studies of dose-response relationships.

Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG.

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):449-462. doi: 10.1080/17425255.2017.1269745. Epub 2016 Dec 20. Review.

PMID:
27927043
12.

An open-label, 6-month study of allopurinol safety in gout: The LASSO study.

Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S.

Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi: 10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21.

13.

An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S44-9. doi: 10.1097/RHU.0b013e31821d352f. Erratum in: J Clin Rheumatol. 2014 Sep;20(6):E3. Naoyuki, Kamatani [Kamatani, Naoyuki]; Shin, Fujimori [corrected to Fujimori, Shin]; Toshikazu, Hada [corrected to Hada, Toshikazu]; Tatsuo, Hosoya [corrected to Hosoya, Tatsuo]; Kenjiro, Kohri [corrected to Kohri, Kenjiro]; Toshitaka, Nakamura [corrected to Nakamura, Toshitaka]; Takanori, Ueda [corrected to Ueda, Takanori]; Tetsuya, Yamamoto [corrected to Yamamoto, Tetsuya]; Hisashi, Yamanaka [corrected to Yamanaka, Hisashi]; Yuji, Matsuzawa [Matsuzawa, Yuji].

PMID:
21654269
14.

Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.

Perez-Ruiz F, Calabozo M, Herrero-Beites AM, García-Erauskin G, Pijoan JI.

Nephron. 2000 Nov;86(3):287-91.

PMID:
11096285
15.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.

N Engl J Med. 2005 Dec 8;353(23):2450-61.

16.

[Quality of treatment in gouty patients considering EULAR recommendations].

Radak-Perović M, Zlatković-Svenda M.

Srp Arh Celok Lek. 2012 Nov-Dec;140(11-12):717-21. Serbian.

17.

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E.

Ann Rheum Dis. 1998 Sep;57(9):545-9.

18.
19.

Urate-lowering therapy for gout: focus on febuxostat.

Love BL, Barrons R, Veverka A, Snider KM.

Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594. Review.

PMID:
20500048
20.

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.

Panomvana D, Sripradit S, Angthararak S.

J Clin Rheumatol. 2008 Feb;14(1):6-11. doi: 10.1097/RHU.0b013e318164dceb.

PMID:
18431090

Supplemental Content

Support Center